Wird geladen...
NIMG-93. DISCRIMINATION OF CLINICALLY IMPACTFUL TREATMENT RESPONSE IN RECURRENT GLIOBLASTOMA PATIENTS RECEIVING BEVACIZUMAB TREATMENT
INTRODUCTION: Clinicians have few effective tools for assessing treatment response in glioblastoma that are predictive of patient outcomes. In previous work, a personalized response metric based on a proliferation-invasion tumor mathematical model, Days Gained, was prognostic for progression-free an...
Gespeichert in:
| Veröffentlicht in: | Neuro Oncol |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Oxford University Press
2017
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5692666/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.662 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|